CLINICAL DIAGNOSTIC STATUS OF MYELITIS DEVELOPED AFTER COVID-19

Yakubova Markhamat Mirakramovna Doliyeva Gulasal Anvar kizi Tashkent medicine academy

Annotation. The COVID-19 pandemic human to the body wide comprehensive impact showing, not only breath ways, maybe central nerve damage to the system reason Research has shown that COVID-19 infection then various neurological complications, including transverse myelitis development This is showing. with COVID-19 in the article related myelitis development mechanism, clinical symptoms, diagnosis and treatment methods analysis MRI, CSF analysis and immunological tests results based on of patient's general status evaluated, corticosteroids and immunoglobulin therapy efficiency Research results with COVID-19 related myelitis early determination and effective treatment strategies working to go out will help.

Key Keywords: COVID-19, **transverse** myelitis, central nerve system, immune answer, corticosteroid therapy, MRI diagnostics, neurological complications, autoimmune reaction.

Introduction COVID-19 pandemic human to your health many complicated effects showed. Initially it was mainly breath of the roads infection as studied if, then organism other systems, including central nerve seriously to the system impact to show World health storage According to the World Health Organization (WHO), according to, with COVID-19 sick of patients about 30% different neurological complications This is observed. complications transverse myelitis among important place From the virus then developing neurological complications transverse myelitis among separately place Transverse myelitis back brain inflammation disease is, its as a result nerve impulses to pass will break and movement, sensation in patients and other neurological functions decrease This is observed. in the article after COVID-19 observable myelitis development mechanism, diagnostics and treatment methods surrounding seeing is released.

Transverse myelitis is back brain inflammation with passing disease become, nerve impulses the passage breaks and movement, sensation in patients and other neurological functions to decrease take Myelitis pathogenesis still complete unexplored Although the COVID-19 virus immune to the system was impact as a result autoimmune reaction formed , nerve tissue to injury reason to be possibility identified . Doctor and scientists this the situation organism too much outside immune The answer is " cytokine " with " storm " (Kerr et al., 2021).

Some research after COVID-19 developed myelitis of the circumstances diagnostics and clinical past according to important information presented For example, Lucchinetti and his/her colleagues (2022) held research to the results according to, with COVID-19 sick patients from 5-7 weeks after myelitis symptoms development observed. Researchers this the situation of the virus nerve to the system directly or indirectly impact with explained.

Therefore, this in the article after COVID-19 observable myelitis development mechanism, diagnostics and treatment methods surrounding seeing The disease is clinical symptoms, immunological mechanisms and therapeutic approaches about discussion will be done.

Methods This research retrospective analysis based on take The research is scheduled for 2020-2024. with COVID-19 in the sick and later transverse myelitis diagnosis placed patients' attraction The research was conducted within following diagnostic from methods used:

• Magnetic resonance imaging tomography (MRI) – back brain structure inflammation processes with related changes determination for.

• Back brain cerebrospinal fluid (CSF) analysis – infection and immunological changes determination for the purpose studied.

• **Immunological tests** – COVID-19 specific antibodies and autoimmune of processes that there is check for was used.

• **Clinical observations** – patients symptoms, complaints and neurological status analysis was done .

Results. Research 50 people within patient studied. Patients in the majority (70%) of cases of the disease first sign as paresthesia (in the arms and legs) (to be) and muscle weakness MRI scans were observed . back brain cervical and thoracic in the fields inflammation processes showed. Back brain liquid in the analyses inflammation high at the level that and some in cases to the virus typical antibodies existence determined.

Treatment methods as corticosteroid therapy and immunoglobulins Corticosteroids inflammation processes in reduction effective is, most of in patients clinical of the situation to improve take Immunoglobulin therapy autoimmune mechanisms based on developed myelitis in cases used and positive results Treatment done The condition is present in 60% of patients much improved, 30% partially improvement observed , and in 10% noticeable improvement record not yet arrived .

Discussion. COVID-19 infection then some in patients central nerve system inflammation diseases, including myelitis development Myelitis is a back brain inflammation is neurological symptoms with manifestation This will be situation autoimmune reactions or of the virus straight away neurotropic impact as a result to the surface arrival possible.

With COVID-19 related myelitis in cases patients often in the limbs weakness, feeling disorders, reflexes decrease or loss such as signs They notice. Some in patients and pee and intestine functions violation is observed.

Diagnostics for magnetic resonance imaging tomography (MRI) and back brain liquid analysis Treatment usually corticosteroids, immunoglobulins and immunosuppressive preparations through take will go . After COVID-19 developed myelitis own on time determination and treatment of patient's life quality for important is considered.

After COVID-19 developing myelitis pathogenesis complete unexplored although, there is to the evidence according to , it is autoimmune processes with related to be The virus is in the body . immune system wrong activation reason myelin floor to injury take Myelitis developed of patients most of them from COVID-19 infection then 2-6 weeks pass neurological symptoms appearance to be observed. This is immunity system postviral reactive answer with related to be possible shows.

Treatment methods efficiency of the disease weight to the level related. Early diagnosis and immunosuppressive therapy when used of patients recovery probability high However, some in cases myelitis permanent neurological to complications take arrival possibility record was made. Future research with COVID-19 related myelitis genetic, immunological and molecular mechanisms further deeper to study focus necessary.

Conclusion After COVID-19 developed myelitis less common, but serious from complications one The disease is clinical past various patients in most cases immune answer because of develops. Diagnostics and in treatment complex approach important importance has especially MRI and CSF examinations the disease clear in determining main role plays. Corticosteroid and immunoglobulin therapy effective patients clinical status to improve help gives. Future research on COVID- 19 neurological complications deeper to study focus This is necessary. research neurological complications development mechanism better to understand help gives and effective treatment methods working on the way-out basis to be service does.

Used literature:

- Schulte E. C. et al. Systematic review of cases of acute myelitis in individuals with COVID-19 //European journal of neurology. – 2021. – T. 28. – №. 10. – C. 3230-3244.
- Ostovan V. R. et al. Clinical characteristics, radiological features and prognostic factors of transverse myelitis following COVID-19 vaccination: A systematic review //Multiple Sclerosis and Related Disorders. – 2022. – T. 66. – C. 104032.
- 3. Chow C. C. N. et al. Acute transverse myelitis in COVID-19 infection //BMJ

Case Reports CP. – 2020. – T. 13. – №. 8. – C. e236720.

- **4.** Gao J. J. et al. Acute transverse myelitis following COVID-19 vaccination //Vaccines. – 2021. – T. 9. – №. 9. – C. 1008.
- 5. Gao J. J. et al. Acute transverse myelitis following COVID-19 vaccination //Vaccines. - 2021. - T. 9. - №. 9. - C. 1008.
- **6.** Yakubova M. M., Mukhiddinova M. A. Change in lipoprotein with multiple sclerosis in the proces of demyelination : дис. Tashkent Medical Academy, 2018.
- Mirakramovna Y. M. et al. Determination of the clinical-neurological characteristics of multiple sclerosis and the relationship of s-100 oxide and lipoproteids //Journal of new century innovations. 2024. T. 47. №. 3. C. 64-70.
- Mirakramovna Y. M., Kutbiddinovna R. G., Karimdzhanovna S. A. S. Clinical and Neurological Features with Covid-19 Associated Cavernous Sinus Thrombosis //Zhongguo Kuangye Daxue Xuebao. – 2024. – T. 29. – №. 3. – C. 224-229.
- **9.** Abzalova M. B. et al. Uyqu va insult. Yuzaga kelishi va kechishi xususiyatlari //Журнал гуманитарных и естественных наук. 2024. №. 13. С. 8-12.
- Якубова М. М. Uyqu va insult. Yuzaga kelishi va kechishi xususiyatlari. 2024.